Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nestle Carnation Ad Claims "Denigrating" To Other Infant Formulas - NAD

This article was originally published in The Tan Sheet

Executive Summary

Nestle USA should cease referring to competing infant formulas as "starter" formulas in its advertising for Carnation Follow-Up, the National Advertising Division of the Council of Better Business Bureaus rules in its May NAD Case Reports.

You may also be interested in...



Nestle Carnation Good Start Infant Formula "Comfort Proteins" Unique - NAD

The hydrolyzed whey "Comfort Proteins" in Nestle's Carnation Good Start infant formulas are unique to the product and do not mislead consumers, the National Advertising Division of the Council of Better Business Bureaus rules in its November NAD Case Reports.

Enfamil Breast Milk Composition Claims Should Be Modified - NARB

Mead Johnson Advanced Formula Enfamil with Iron breast milk composition claims should be discontinued unless specific conditions are met, the National Advertising Review Board recommends, upholding an earlier National Advertising Division decision.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel